Last reviewed · How we verify
Rosuvastatin plus ticagrelor — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rosuvastatin plus ticagrelor (Rosuvastatin plus ticagrelor) — Federal University of São Paulo.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rosuvastatin plus ticagrelor TARGET | Rosuvastatin plus ticagrelor | Federal University of São Paulo | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rosuvastatin plus ticagrelor CI watch — RSS
- Rosuvastatin plus ticagrelor CI watch — Atom
- Rosuvastatin plus ticagrelor CI watch — JSON
- Rosuvastatin plus ticagrelor alone — RSS
Cite this brief
Drug Landscape (2026). Rosuvastatin plus ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-plus-ticagrelor. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab